Evonik stock holds in high-teens as interim CEO move and profit outlook shape 2026 rerating
Published on 08/29/2026 at 10:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evonik Industries AG (ISIN DE000EVNK013) stock is trading in the high-teens euro range as of August 28, 2026, with market snapshots showing quotes between EUR 18.31 and EUR 18.75 and year-to-date gains of up to 40.49 percent according to recent market data https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. The shares have been supported by an improved full-year profit outlook and investor attention on an interim leadership arrangement starting September 1, 2026, following a recent change in top management responsibilities https://www.chemicalprocessing.com/industrynews/news/55401542/evonik-names-interim-ceo-plans-108m-drug-manufacturing-facility-in-canada.
Leadership transition with interim CEO
Recent reporting on August 28, 2026 highlights that Evonik has appointed Claus Rettig to its executive board and named him deputy chairman effective September 1, 2026 while CEO Christian Kullmann recovers from surgery https://www.chemicalprocessing.com/industrynews/news/55401542/evonik-names-interim-ceo-plans-108m-drug-manufacturing-facility-in-canada. The interim arrangement is designed to maintain operational continuity at the specialty chemicals group while the CEO is temporarily absent.
On the same date, a separate report focusing on Evonik stock notes that investors have been digesting this leadership transition with only modest day-to-day price swings, as quotes on August 27, 2026 showed EUR 18.31 on Xetra and EUR 18.75 on Tradegate, implying a daily change of 1.29 percent down on Xetra but a 1.24 percent gain in another venue https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. The corridor from EUR 18.31 to EUR 18.75 places the stock comfortably above levels seen at the start of 2026, underscoring that the management news has not derailed the broader upward trend.
2026 rerating supported by profit outlook
The same stock-focused report dated August 28, 2026 states that Evonik shares are up between 38.98 percent and 40.49 percent since January 1, 2026 based on different European trading venues, with recent prices clustered between EUR 18.49 and EUR 18.75 https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. This quantified year-to-date performance points to a significant rerating relative to early 2026 levels and places the company among the stronger performers within the German chemicals segment.
The same coverage also notes that Evonik has signaled an improved full-year profit outlook for 2026, which is cited by market observers as a key factor behind the higher valuation band https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. While the report does not provide precise revenue, EBIT or net income figures for the latest quarter, it indicates that the upgraded guidance has been an important catalyst for the stock, suggesting that profitability expectations have risen compared with prior assumptions earlier in the year.
Weekly performance data compiled for MDAX constituents published on August 29, 2026 shows that Evonik delivered a gain of 2.23 percent over the referenced week, placing the stock mid-field among index members https://www.finanzen.net/nachricht/aktien/performance-kw-35-die-gewinner-und-verlierer-der-mdax-aktien-der-vergangenen-woche-15896620. This weekly rise complements the year-to-date increase of up to 40.49 percent and indicates that the positive trend has continued into the later part of August 2026, even as the leadership change became public knowledge.
Sector backdrop and valuation context
The late-August 2026 analysis of Evonik stock emphasizes that the broader German chemical industry has benefited from a brighter sentiment environment, with improved demand expectations and easing cost pressures cited as supportive factors for sector valuations https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. For Evonik, the combination of this sector tailwind and the company-specific guidance upgrade has helped justify trading levels around EUR 18.5 to EUR 18.75.
At the same time, market commentary stresses that the high-teens price range still reflects a balance of opportunity and risk, as investors monitor how the interim leadership structure functions through the remainder of 2026 and how quickly demand in key end markets normalizes. The tight corridor of recent quotes between EUR 18.31 and EUR 18.75 over August 27-28, 2026, alongside daily moves close to plus or minus 1 percent, suggests a market that is cautiously constructive but sensitive to new information https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669.
Read more
Further details on Evonik investor relations provide broader context on the company and its financial communication.
Specialty chemicals and drug manufacturing expansion
Evonik's business model centers on specialty chemicals serving market segments ranging from nutrition and care to resource efficiency and performance materials, which supply additives and intermediates to a wide variety of industrial customers https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. In late August 2026, the company also highlighted plans for a drug manufacturing facility investment in Canada, with a reported project size of $108 million aimed at expanding its capabilities in pharmaceutical contract manufacturing https://www.chemicalprocessing.com/industrynews/news/55401542/evonik-names-interim-ceo-plans-108m-drug-manufacturing-facility-in-canada.
This planned $108 million facility is intended to strengthen Evonik's footprint in high-value pharmaceutical ingredients and contract production services, areas that are typically less cyclical than basic chemicals. For investors, such projects illustrate how the group is leaning toward more specialized and potentially higher-margin activities, aligning the capital expenditure program with its positioning as a specialty chemicals provider.
Evonik stock on European exchanges
Market snapshots around August 28, 2026 show Evonik shares quoted at EUR 18.31 on Xetra and at EUR 18.75 on Tradegate, corresponding to single-session moves of minus 1.29 percent and plus 1.24 percent respectively https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. These differences illustrate the usual venue-based dispersion but confirm that the stock is consolidating in the high-teens range after its strong 2026 run.
As of the latest available consolidated data around August 28, 2026, Evonik stock trades in a corridor bounded by EUR 18.31, EUR 18.49, and EUR 18.75 across key European venues, with year-to-date performance indicated between 38.98 percent and 40.49 percent depending on the precise reference quote https://www.ad-hoc-news.de/boerse/news/corporate-news/evonik-stock-steadies-as-interim-ceo-appointment-and-upbeat-sector-mood/70014669. The combination of this performance and the upgraded profit outlook frames the current valuation debate for the shares.
Fact box
Company: Evonik Industries AG
ISIN: DE000EVNK013
Ticker: EVK
Exchange: Xetra
Sector / Industry: Specialty chemicals
